Keyuan Pharmaceutical announced that recently, its wholly-owned subsidiary Linuo Pharmaceutical received an approval notice for the drug supplement application, and the marketing license holder for betahistine hydrochloride tablets was changed to Linuo Pharmaceuticals. At the same time, Linuo Pharmaceuticals participated in the 12th batch of nationally organized drug procurement bids. Products such as injectable isaconazole sulfate were selected, and the companies to be selected for betastine hydrochloride tablets will later be changed to Linuo Pharmaceuticals. The procurement period starts on the execution date of the selected results and ends on December 31, 2029. It has been approved this time and plans to be selected or improve performance, but there is still uncertainty about the future.

Keyuan Pharmaceutical announced that recently, its wholly-owned subsidiary Linuo Pharmaceutical received an approval notice for the drug supplement application, and the marketing license holder for betahistine hydrochloride tablets was changed to Linuo Pharmaceuticals. At the same time, Linuo Pharmaceuticals participated in the 12th batch of nationally organized drug procurement bids. Products such as injectable isaconazole sulfate were selected, and the companies to be selected for betastine hydrochloride tablets will later be changed to Linuo Pharmaceuticals. The procurement period starts on the execution date of the selected results and ends on December 31, 2029. It has been approved this time and plans to be selected or improve performance, but there is still uncertainty about the future.